BrianJ.MillerMD

Professor, Psychiatry & Health Behavior, Medical College of Georgia at Augusta University

Dr. Miller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Brian Miller is a psychiatrist in Augusta, GA and is affiliated with Augusta University Medical Center. He received his medical degree from Ohio State University College of Medicine and has been in practice 13 years. He is experienced in schizophrenia and psychotic disorders. He has more than 100 publications and over 500 citings.

An Open-Label Trial of Tocilizumab in Schizophrenia Start of enrollment: 2012 Sep 01
Completed
Phase 1
Tocilizumab in Schizophrenia Start of enrollment: 2016 Sep 01
Recruiting
Phase 1
Roles: Sponsor-Investigator, Principal Investigator, Contact
Siltuximab in Schizophrenia Start of enrollment: 2016 May 01
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact, Sponsor-Investigator

PubMed

1083 citations
A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.
David R. Goldsmith, Mark Hyman Rapaport, Brian J. Miller
Molecular Psychiatry. 2016-02-23
877 citations
Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies.
Cristiano A. Köhler, Thiago H. Freitas, Michael Maes, N. Q. De Andrade, Celina S. Liu
Acta Psychiatrica Scandinavica. 2017-05-01
187 citations
C-reactive protein levels in schizophrenia: a review and meta-analysis.
Brian J. Miller, Nick H. Culpepper, Mark Hyman Rapaport
Clinical Schizophrenia & Related Psychoses. 2014-01-01

Journal Articles

Insomnia and Suicidal Ideation in Non-Affective Psychosis
Brian J Miller, Mark H Rapaport, Peter F Buckley, Sleep

Common Blood Test May Provide Insight into Which Patients with Schizophrenia Also at High Risk for Cardiovascular DiseaseSeptember 20th, 2021
The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive DyskinesiaNovember 15th, 2020
Immunotherapy Can Boost Cognitive Function in Schizophrenia PatientsFebruary 29th, 2016